Professor Sujun Han: 2026 NCCN Guideline Update — Urothelial Carcinoma Enters an Era of Precision Medicine and Organ PreservationBeijing Academic Exchange Conference for Young Physicians in Urologic Oncology

Professor Sujun Han: 2026 NCCN Guideline Update — Urothelial Carcinoma Enters an Era of Precision Medicine and Organ PreservationBeijing Academic Exchange Conference for Young Physicians in Urologic Oncology

2026.02.05
At the beginning of 2026, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was grandly held in Beijing. The meeting focused on frontier advances and standardized practices in urologic oncology and brought together numerous domestic experts and scholars in the field.
Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

2026.02.05
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on cutting-edge topics in the diagnosis and treatment of urologic malignancies, aiming to establish a high-level academic exchange platform and to promote innovation in clinical thinking and standardized practice among young physicians.
Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC

Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC

2026.02.04
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on the latest frontiers in urologic oncology and brought together many leading mid-career and young experts from across China, aiming to elevate clinical practice through intellectual exchange.
ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC

ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC

2026.02.04
In the global field of hepatocellular carcinoma (HCC) treatment, the synergistic use of targeted therapy and immunotherapy has led to breakthrough progress, significantly prolonging survival for patients with advanced disease and bringing renewed hope to countless individuals. Yet medical progress never stands still. How to further transcend existing treatment paradigms and unlock deeper survival benefits remains a persistent goal for clinicians worldwide.
ESMO International Perspective | Professor Maria Reig: Large International Multicenter Evidence Supports the Inclusion of EBRT in the BCLC Staging and Treatment Algorithm

ESMO International Perspective | Professor Maria Reig: Large International Multicenter Evidence Supports the Inclusion of EBRT in the BCLC Staging and Treatment Algorithm

2026.02.04
The Barcelona Clinic Liver Cancer (BCLC) staging system is the cornerstone framework guiding treatment decisions for hepatocellular carcinoma (HCC). Its fundamental role lies in stratifying patients according to three key prognostic determinants—tumor burden, liver function, and performance status—thereby aligning prognosis assessment with evidence-based treatment recommendations for each disease stage.
ESMO International Perspective | 42-Month Long-Term Follow-Up with Median OS of 22.8 Months: Professor Manon Allaire Interprets the Outstanding Real-World Performance of the “T+A” Regimen

ESMO International Perspective | 42-Month Long-Term Follow-Up with Median OS of 22.8 Months: Professor Manon Allaire Interprets the Outstanding Real-World Performance of the “T+A” Regimen

2026.02.04
The combination of atezolizumab plus bevacizumab (the “T+A” regimen) has established a new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the lack of long-term survival data and uncertainties regarding its effectiveness in complex real-world populations have remained major clinical concerns.
ESMO International Perspective | Global Lung Cancer Experts Discuss the OptiTROP-Lung04 Study: Sacituzumab Tirumotecan Breaks Through Post-TKI Resistance

ESMO International Perspective | Global Lung Cancer Experts Discuss the OptiTROP-Lung04 Study: Sacituzumab Tirumotecan Breaks Through Post-TKI Resistance

2026.02.04
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) were among the earliest beneficiaries of precision targeted therapy. However, once tyrosine kinase inhibitor (TKI) resistance develops and disease progression occurs, the choice of subsequent therapy has long posed a major challenge for clinicians worldwide. The emergence of innovative treatments such as antibody–drug conjugates (ADCs) has brought new hope for overcoming this long-standing dilemma.
ESMO Expert Dialogue | From Chinese Innovation to Global Consensus — Landmark Interpretation of TALENTOP and New Horizons in Perioperative Therapy for Liver Cancer

ESMO Expert Dialogue | From Chinese Innovation to Global Consensus — Landmark Interpretation of TALENTOP and New Horizons in Perioperative Therapy for Liver Cancer

2026.02.04
Hepatocellular carcinoma (HCC) remains one of the deadliest malignancies worldwide. Approximately 60–70% of patients are diagnosed at intermediate or advanced stages, making the pursuit of innovative therapeutic strategies that deliver meaningful survival benefit a long-standing global challenge. Against this backdrop, the TALENTOP study, led by Fan Jia, Academician and Principal Investigator from Zhongshan Hospital, Fudan University, and presented orally at ESMO 2025 by Sun Huichuan, has drawn worldwide attention.
ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC

ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC

2026.02.03
The Phase III BURAN trial, presented at the recent ESMO Congress, evaluated the PI3K inhibitor buparlisib plus paclitaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who had progressed after PD-1/PD-L1 inhibitor therapy. The study failed to demonstrate improvements in progression-free survival (PFS) or overall survival (OS) compared with paclitaxel alone (median PFS: 4.1 months in both arms; median OS: 9.6 vs 9.7 months), despite a higher objective response rate (ORR) with the combination (30.3% vs 20.7%).
ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care

ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care

2026.02.03
With the rapid evolution of immunotherapy–targeted therapy combinations, the management of advanced hepatocellular carcinoma (HCC) has entered a new era. Yet for patients with traditionally high-risk features—such as macrovascular invasion or extrahepatic spread—clinical outcomes have historically remained poor, posing a persistent therapeutic challenge.